Ferroptosis is a form of regulated cell death that has captivated oncologists since its discovery. Unlike apoptosis, the tidy, programmed dismantling of a cell, ferroptosis is a violent, iron-driven process in which reactive oxygen species attack the fatty membranes that enclose cells. Lipid peroxidation spreads like a chemical wildfire until the membrane disintegrates. Under the microscope, cells dying by ferroptosis display shrunken mitochondria with increased membrane density and diminished cristae, the internal folds where respiration takes place. Because cancer cells run metabolically hot, accumulating oxidative stress as a byproduct of their rapid growth, they are often unusually vulnerable to this mode of death, making ferroptosis an attractive therapeutic lever.

The central antioxidant defense against ferroptosis is the glutathione peroxidase 4 enzyme, or GPX4, which detoxifies phospholipid hydroperoxides using glutathione as a cofactor. Starving cells of cysteine, the amino acid required to build glutathione, collapses this defense system. Cysteine depletion does more than drain glutathione: it also impairs the synthesis of coenzyme A, disrupting lipid metabolism, and destabilizes iron-sulfur clusters, which activates an iron-starvation response that increases iron uptake through the transferrin receptor. The result is an expanding pool of unliganded ferrous iron that fuels Fenton chemistry, generating a flood of reactive oxygen species and driving lethal lipid peroxidation. A compound called RSL3 can trigger the same endpoint more directly by binding to and inhibiting GPX4 outright.

Lapatinib, meanwhile, is an orally available small-molecule inhibitor that selectively blocks the tyrosine kinase activities of the epidermal growth factor receptor EGFR and its relative HER2, suppressing the downstream MAPK and PI3K/AKT survival pathways that tumors depend on. Previous studies had painted a confusing picture of its relationship with ferroptosis. In breast cancer cells, lapatinib promoted ferroptosis when combined with a lysosome-disrupting agent, accompanied by iron accumulation. More recently, it was reported to induce ferroptosis in osteosarcoma by disrupting glutamine uptake and glutathione synthesis. Yet in neuronal cells, lapatinib was found to suppress ferroptosis by restoring GPX4 expression. The new study set out to resolve how the drug behaves when ferroptosis is induced by cysteine deprivation in non-small cell lung cancer cells.

The research team, led by investigators at the Korea Institute of Radiological and Medical Sciences and collaborating institutions, worked with two human lung cancer cell lines, H1299 and H23. When the cells were deprived of cysteine for 24 hours, viability in H1299 cells collapsed to roughly 30 percent of control levels. Remarkably, adding lapatinib restored viability in a dose-dependent manner, climbing back to about 65 percent at a concentration of 10 micromolar. In H23 cells, where cysteine deprivation cut viability to about a quarter of normal, lapatinib again rescued the cells dose-dependently. Crucially, two other EGFR-targeting drugs, erlotinib and gefitinib, offered no such protection, indicating that the effect is not a generic property of this drug class.

To confirm that the cell death in question was truly ferroptosis, the researchers deployed a panel of benchmark compounds. Ferrostatin-1 and liproxstatin-1, both inhibitors of lipid peroxidation, and deferoxamine, an iron chelator, all significantly blunted the viability loss caused by cysteine deprivation, whereas z-VAD-fmk, an apoptosis blocker, had no effect. That pharmacological fingerprint pointed squarely at ferroptosis. The team then measured malondialdehyde, a major end product of lipid peroxidation, and used the C11-BODIPY fluorescent probe to visualize membrane oxidation directly. Cysteine deprivation drove both markers sharply upward, and lapatinib pulled them back down in both cell lines, confirming that the drug was suppressing the lipid peroxidation cascade at its core.

The mechanistic surprises deepened from there. Cysteine deprivation and lapatinib each independently raised intracellular reactive oxygen species and ferrous iron levels when given alone. Yet when lapatinib was combined with cysteine deprivation, it significantly reduced ROS generation even though intracellular ferrous iron remained elevated, comparable to levels seen with lapatinib alone. Even more counterintuitively, lapatinib further depleted glutathione and further reduced GPX4 protein expression under cysteine-deprived conditions, the opposite of what a ferroptosis-suppressing intervention would be expected to do through the canonical antioxidant pathway. The drug also protected cells from RSL3, the direct GPX4 inhibitor, while again lowering GPX4 expression further, demonstrating that its protective effect operates entirely independently of the glutathione-GPX4 axis.

The answer, the researchers found, lies in the mitochondria. Both cysteine deprivation and RSL3 treatment caused hyperpolarization of the mitochondrial membrane potential, detected by increased TMRE fluorescence, along with a marked rise in oxygen consumption, signatures of revved-up mitochondrial metabolism that have previously been linked to mitochondrial ROS generation and ferroptotic death. Lapatinib alone produced only modest increases in these parameters, but when co-administered with either ferroptotic stimulus, it significantly blunted both the membrane hyperpolarization and the surge in oxygen consumption. By restraining excessive mitochondrial metabolic activation, lapatinib appears to cut off the supply of mitochondrial ROS that sustains lipid peroxidation, rendering the accumulated ferrous iron insufficient to keep the ferroptotic fire burning.

Why would lapatinib calm mitochondrial respiration? The authors point to a tantalizing clue from a recent computational study predicting that lapatinib interacts with SLC1A5, a glutamine transporter. Glutaminolysis, the conversion of glutamine into alpha-ketoglutarate that feeds the tricarboxylic acid cycle, is indispensable for cysteine deprivation-induced ferroptosis, because it supplies the mitochondrial fuel that drives the respiratory surge. If lapatinib disrupts glutamine metabolism, reduced glutaminolysis would dampen mitochondrial activation and thereby limit ROS generation, a hypothesis consistent with the team’s observations. The precise molecular mechanism, however, remains to be worked out, and the researchers are careful to frame this as a hypothesis rather than a settled explanation.

The therapeutic implications cut in an uncomfortable direction. Ferroptosis induction is increasingly viewed as a way to overcome resistance to conventional agents such as cisplatin, docetaxel and sorafenib, and to amplify the effects of chemotherapy, radiotherapy and immunotherapy. If lapatinib suppresses ferroptosis that depends on mitochondrial metabolic activation, then combining it with such strategies could inadvertently blunt their efficacy and contribute to therapeutic resistance. The study also reinforces a broader lesson now echoing through the ferroptosis field: drug effects on this cell death pathway are exquisitely context-dependent, shaped by cell type, metabolic state and the specific trigger involved. A drug that kills by ferroptosis in one setting may protect against it in another, and clinicians designing rational combinations will need to account for that metabolic fine print.

Subject of Research: Context-dependent regulation of ferroptotic cell death by the EGFR/HER2 inhibitor lapatinib in non-small cell lung cancer cells

Article Title: Lapatinib suppresses cysteine deprivation-induced ferroptotic cell death by modulating mitochondrial function

Article References: Kim, G., Jang, S.-K., Kim, D.-G., Kim, H., Hong, J., Park, I.-C., & Jin, H.-O. (2026). Lapatinib suppresses cysteine deprivation-induced ferroptotic cell death by modulating mitochondrial function. Medical Oncology, 43(11), Article 294. https://doi.org/10.1007/s12032-026-03402-7

Image Credits: AI Generated

DOI: 10.1007/s12032-026-03402-7

Keywords: lapatinib, ferroptosis, cysteine deprivation, mitochondria, GPX4, glutathione, lipid peroxidation, reactive oxygen species, non-small cell lung cancer, EGFR inhibitors, RSL3, mitochondrial membrane potential

The biology underlying the problem begins with the receptor itself. HER2 is overexpressed in roughly 25 to 30 percent of breast cancers, and since its amplification was first linked to aggressive disease and poor survival in the 1980s, it has served as the archetype of a druggable oncogenic target. The monoclonal antibody trastuzumab, clinically available since the early 2000s, dramatically improved survival outcomes, an effect consolidated in landmark trials such as HERA, which reported asymptomatic declines in left ventricular ejection fraction in about 7 percent of patients, and BCIRG-006, where the figure climbed to 18.6 percent. A 2019 pooled analysis of the major adjuvant trastuzumab trials, encompassing HERA, NSABP B-31, and N9831, placed the prevalence of trastuzumab-related cardiotoxicity at 11.3 percent asymptomatic and 8.7 percent mildly symptomatic. Broader analyses put the incidence of cardiotoxicity at 14.3 percent with trastuzumab alone, rising to 17.9 percent when the dual antibody blockade of trastuzumab and pertuzumab is added.

The mechanistic explanation for this cardiac vulnerability is now reasonably well understood. Cardiomyocytes depend on HER2 signaling for survival and repair, and blocking the receptor triggers cardiomyocyte death through mitochondrial dysfunction and reactive oxygen species-dependent pathways, while also shifting the balance of anti-apoptotic and pro-apoptotic proteins within heart muscle cells. Trastuzumab additionally works through antibody-dependent cellular cytotoxicity, an immune mechanism that contributes to its anticancer potency but may compound cardiac injury. For patients whose left ventricular ejection fraction remains above 40 percent, the prospective SAFE-HEaRt study demonstrated that trastuzumab can be delivered with acceptable safety. Below that threshold, however, the evidence base thins dramatically, and trastuzumab is considered contraindicated. Guidance on preventing and monitoring cardiac dysfunction in cancer survivors exists, but for patients starting treatment with established cardiomyopathy and an ejection fraction below 40 percent, published guidance is scarce and the literature is sparse.

It was into this evidentiary vacuum that the Bengaluru patient arrived. A frail 65-year-old woman weighing just 38.5 kilograms, she had lived with ischemic cardiomyopathy since 2014 and was managing New York Heart Association class II heart failure with a regimen that included furosemide, aspirin, spironolactone, atorvastatin, carvedilol, digoxin, and nitroglycerin. In July 2023 she noticed a lump in her right breast. Biopsy revealed invasive breast carcinoma of grade 2, estrogen receptor positive in 15 percent of cells, progesterone receptor negative, HER2-positive with 3-plus staining in 95 percent of cells, and a Ki67 proliferation index of 25 percent. Imaging confirmed a heterogeneously enhancing lobulated mass in the lower inner quadrant of the right breast, along with necrotic deep pectoral lymph nodes, establishing early-stage disease that had not invaded skin or muscle. Baseline echocardiography, however, recorded a left ventricular ejection fraction of just 32 percent, placing trastuzumab and pertuzumab, the mainstays of HER2-positive breast cancer therapy, off the table.

The clinical team turned instead to lapatinib, an oral small-molecule tyrosine kinase inhibitor that dually targets HER2 and HER1. The pharmacological argument for this choice is layered. Pooled data from 3,689 patients across clinical trials, along with a meta-analysis of 26 studies, established that lapatinib carries a markedly lower cardiac risk, with reductions in ejection fraction, arrhythmia, and other cardiac adverse events occurring in roughly 3 percent of patients, and individual reports ranging between 1.6 and 4.5 percent. Unlike trastuzumab, lapatinib does not induce antibody-dependent cellular cytotoxicity, and it lacks the apoptosis-inducing property that contributes to cardiomyocyte death. Critically, its pharmacokinetic profile is far more forgiving: while trastuzumab circulates for a half-life of 16 days, pertuzumab for 18 days, and the antibody-drug conjugate T-DM1 for 4 days, lapatinib’s half-life is just 14.2 hours. That short duration means any adverse effect on the heart can be reversed rapidly, and the dose can be titrated or withheld entirely at short notice, an impossibility with long-acting antibodies that linger in the circulation for weeks.

The treatment plan was built around these pharmacological advantages. The patient received 12 weekly doses of nanoparticle albumin-bound paclitaxel together with lapatinib 250 milligrams once daily, with intravenous fluids restricted to avoid volume overload in her failing heart. A dedicated cardio-oncologist monitored her with weekly clinical assessments and monthly echocardiograms. After four weeks, the breast lump had shrunk from 4 by 3 centimeters to 2 by 2 centimeters, axillary nodes had diminished, and her ejection fraction held steady at 32 percent. Encouraged by her tolerance, the team escalated lapatinib to 500 milligrams daily and added weekly carboplatin. By eight weeks the tumor measured under 1 centimeter and cardiac function remained stable at 31 percent. A further escalation to 750 milligrams proved too much, producing increasing diarrhea that forced a return to the 500-milligram dose, a textbook illustration of how the oral agent’s dose flexibility allows real-time optimization in a way infusible antibodies cannot match.

After the full 12 weeks of neoadjuvant therapy, the patient requested a break to pursue local treatments. Positron emission tomography-computed tomography demonstrated a complete metabolic response, confirming that the tumor had been eradicated morphologically and metabolically. Surgery, however, presented an unacceptable risk. Given her ejection fraction of 32 percent with dilated cardiomyopathy, the Seattle Heart Failure Model predicted a five-year mortality of 35 percent, and the patient declined to accept the high probability of peri-operative cardiac complications even after cardiology clearance. The team pivoted to definitive external beam radiation to the right breast, supraclavicular fossa, and axilla, delivering 40 Gy in 15 fractions with a 12.5 Gy boost in 5 fractions to the tumor bed, followed by hormonal therapy with an aromatase inhibitor for five years and continued lapatinib for up to two years. At two years of follow-up, she remains free of disease on clinical examination and imaging, with her cardiac function never having deteriorated during treatment.

The case carries implications beyond a single patient. The authors note that to their knowledge this is the first published description of neoadjuvant lapatinib-based therapy for HER2-positive breast cancer in a patient with pre-existing cardiomyopathy and an ejection fraction below 40 percent, and they frame it as highlighting a genuine gap in the literature. Newer and more potent HER2-targeted kinase inhibitors may extend this strategy: neratinib and tucatinib have both shown cardiac dysfunction rates below 3 percent in pivotal trials, suggesting a growing armamentarium of heart-sparing oral agents for this vulnerable population. The authors also acknowledge the trade-off candidly, noting that lapatinib may be less effective than monoclonal antibodies at engaging immune pathways through antibody-dependent cellular cytotoxicity. In this patient, however, that pharmacological compromise proved more than sufficient, delivering a complete metabolic response without a single beat of additional cardiac damage. For the growing cohort of cancer patients with compromised hearts, the case offers a practical roadmap: choose agents with short half-lives, titrate carefully under dedicated cardio-oncology surveillance, and let pharmacokinetics do the protective work that antibodies cannot.

As targeted cancer therapy continues to expand, the intersection of oncology and cardiology will only grow more crowded. Cardio-oncology, the discipline embodied by the monthly echocardiographic monitoring in this case, is rapidly becoming an essential partner in curative cancer care. The Bengaluru report demonstrates that a contraindication on a drug label need not translate into a forgone chance at cure. By understanding the molecular reasons why HER2 blockade injures the heart, and by selecting inhibitors whose kinetics allow rapid withdrawal, clinicians can walk the tightrope between tumor and myocardium, and occasionally, as in this case, reach the other side with both the cancer and the heart intact.

Subject of Research: Use of the HER2-targeted tyrosine kinase inhibitor lapatinib to treat HER2-positive breast cancer in a patient with pre-existing cardiac dysfunction

Article Title: Targeting HER-2 pathway in presence of cardiac dysfunction: the walk on a tight rope

Article References: Simha, V., Raj, B., Munirathna, V., & Anantharamu, S. (2026). Targeting HER-2 pathway in presence of cardiac dysfunction: the walk on a tight rope. Clinical Cancer Bulletin, 5(1), Article 12. https://doi.org/10.1007/s44272-026-00064-4

Image Credits: AI Generated

DOI: 10.1007/s44272-026-00064-4

Keywords: HER2-positive breast cancer, lapatinib, cardiotoxicity, trastuzumab, cardiac dysfunction, tyrosine kinase inhibitor, neoadjuvant chemotherapy, cardio-oncology, ejection fraction, pertuzumab, drug safety, clinical case report